Phathom Pharmaceuticals (PHAT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.04
- Estimate
- $0.03
- Surprise
- +39.9%
- Revenue (period 2026-09-30)
- $84.7M
- Score today
- 6.5/10
Revenue source: xbrl.
How the report landed
Phathom Pharmaceuticals (PHAT) beat the $0.03 estimate with adjusted EPS of $0.04 — a large 39.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAT Hold at 6.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +39.9% surprise compares with a +51.2% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Strong earnings beat streak (3/4)
- Attractive valuation
What argues against it
- Concentration risk — Product: VOQUEZNA
- Concentration risk — Counterparty: Takeda License
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.04
- Price target
- $7.08
- Stop
- $4.86
- Upside to target
- +40.5%
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
PHAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $447.1M
- P/E (fwd)
- 5.8
- 52-week range
- $5.01–$18.31
- Off 52-week high
- 72.5%
- RSI (14)
- 35
- Volume vs avg
- 0.44×
- Score today
- 6.5/10